Zobrazeno 1 - 10
of 13
pro vyhledávání: ''
Publikováno v:
Leukemia & Lymphoma. 59:2220-2226
Acquisition of chemoresistance accounts for a major cause of chemotherapy failure for multiple myeloma (MM). Bone marrow stromal cells (BMSCs) are considered to play a pivotal role in modulating drug resistance of MM cells. However, the underlying me
Autor:
Stefan K. Barta, Joseph A. Sparano, Michelle A. Rudek, Carlyn Rose C. Tan, Ariela Noy, Jeannette Y. Lee
Publikováno v:
Leukemia & Lymphoma. 59:1851-1860
Drug-drug interactions between cART and chemotherapy may impact HIV and lymphoma control or lead to increased toxicities. No prospective comparative data informs potential harms and benefits. In AMC034 HIV-associated high-grade B-cell NHL patients re
Autor:
Stephan Stilgenbauer, Véronique Leblond, Stefan Ibach, Florence Cymbalista, Peter Dreger, Alain Delmer, Daniela Steinbrecher, Hartmut Döhner, Eugen Tausch, Billy Michael Chelliah Jebaraj, Johannes Bloehdorn, Christof Schneider, Jennifer Edelmann, Michael Hallek, Annika Scheffold
Publikováno v:
Leukemia & Lymphoma. 59:1614-1623
Telomere length in chronic lymphocytic leukemia (CLL) is described as an independent prognostic factor based largely on previously untreated patients from chemotherapy based trials. Here, we studied telomere length associations in high-risk, relapsed
Autor:
Malte von Bonin, Nael Alakel, Gerhard Ehninger, Bozena Büttner, Michael Kramer, Holger Knoth, Johannes Schetelig, Uwe Platzbecker, Martin Bornhäuser, Reinhard Oertel, Jan Moritz Middeke, Katja Sockel, Christoph Röllig, Friedrich Stölzel, Andreas Seeling
Publikováno v:
Leukemia & Lymphoma. 58:2865-2874
Common side effects of clofarabine (CFB) are liver toxicity, particularly a transient elevation of transaminases and skin toxicity. We studied the correlation of pharmacokinetic (PK) parameters with these toxicities and the efficacy of CFB in patient
Autor:
José Cervera, Juan Eduardo Megías-Vericat, Antonio Miguel, Luis Rojas, Pau Montesinos, Salvador F. Aliño, José Luis Poveda, Jaime Sanz, María José Herrero, Miguel A. Sanz, Luis Sendra, Ana García-Robles, Rebeca Rodríguez-Veiga, David Martínez-Cuadrón, Ignacio Lorenzo, María Martín-Cerezuela, David Hervás, Blanca Boluda, Virginia Bosó, Federico Moscardó
Publikováno v:
Leukemia & Lymphoma. 58:1197-1206
Anthracycline uptake could be affected by efflux pumps of the ABC family. The influence of 7 SNPs of ABC genes was evaluated in 225 adult de novo acute myeloid leukemia (AML) patients. After multivariate logistic regression there were no significant
Publikováno v:
Leukemia & Lymphoma. 57:1021-1032
Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clin
Publikováno v:
Leukemia & Lymphoma. 57:1507-1516
Recent advances in the treatment of patients with non-Hodgkin lymphoma have driven a paradigm shift from standard chemotherapy to an ever-expanding choice of targeted agents and combinations. As an orally bioavailable immunomodulator with antineoplas
Publikováno v:
Leukemia & Lymphoma. 57:921-926
The constitutive activation of signal transducer and activator of transcription 5 (STAT5) occurs during the transformation of fusion genes in leukemia. We aimed to investigate whether or not the genetic polymorphisms in the STAT5 gene are associated
Autor:
Akiko Matsushita, Sumie Tabata, Noboru Yonetani, Takayuki Ishikawa, Yuichiro Ono, Yukihiro Imai, Nobuhiro Hiramoto, Yotaro Ochi, Satoshi Yoshioka
Publikováno v:
Leukemia & Lymphoma. 57:1945-1948
The number of patients receiving chronic dialysis is increasing worldwide.[1] Patients receiving chronic dialysis have a higher risk of developing some kinds of malignant tumors, including hematolo...
Autor:
James R. Downing, Raul C. Ribeiro, Stanley Pounds, Jatinder K. Lamba, Xueyuan Cao, Jeffrey E. Rubnitz, Sharyn D. Baker, Susana C. Raimondi, Kristine R. Crews, Neha Bhise, Christopher R. Cogle
Publikováno v:
Leukemia & Lymphoma. 57:909-920
Despite initial remission, approximately 60-70% of adult and 30% of pediatric patients experience relapse or refractory AML. Studies so far have identified base line gene expression profiles of pathogenic and prognostic significance in AML, however e